Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 23 | -0.49 Increased by +86.39% | -0.49 |
| Mar 6, 23 | -0.50 Increased by +71.10% | -0.57 Increased by +21.55% |
| Nov 7, 22 | -0.53 Increased by +54.31% | -0.78 Increased by +41.09% |
| Aug 4, 22 | -0.90 Increased by +15.89% | -0.85 Decreased by -6.92% |
| May 6, 22 | -3.60 Decreased by -246.15% | -1.95 Decreased by -43.39% |
| Mar 1, 22 | -1.73 Decreased by -101.16% | -1.31 Decreased by -24.47% |
| Nov 8, 21 | -1.16 Decreased by -34.88% | -1.12 Decreased by -3.19% |
| Aug 9, 21 | -1.07 Decreased by -33.75% | -1.06 Decreased by -0.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -39.76 M Increased by +79.96% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -39.76 M Increased by +85.27% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -30.23 M Increased by +51.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -49.09 M Increased by +14.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -198.40 M Decreased by -257.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -269.86 M Decreased by -509.47% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -62.73 M Decreased by -49.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -57.21 M Decreased by -45.60% | Decreased by N/A% Decreased by N/A% |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.